The Effectiveness of Using Prednisolone in Children with Community – Acquired Pneumonia

Nematullo Sadikov¹*, Xu Chao Yue¹, Xin Zhi Hong¹, Bekzod Odilov¹ and Zhang Zhao Hua¹

¹Department of Pediatrics, School of Clinical Medicine Shandong University, Jinan, Shandong, China.

Authors’ contributions

This work was carried out in collaboration among all authors. Author NS designed the study, performed the statistical analysis and wrote the first draft of the manuscript. Authors XCY and XZH managed the analyses of the study. Author BO managed the literature searches. Author ZZH wrote the protocol. All authors read and approved the final manuscript.

ABSTRACT

Community-acquired Pneumonia (CAP) is an infection of the lung parenchyma that is acquired outside of hospital, [1] involved approximately 150 million new cases annually, among children younger than 5 years old worldwide. We retrospectively evaluated the effect of Prednisolone in 89 children with CAP who were admitted to the 2nd hospital of Shandong University (China) and Infectious diseases of Andijon region (Uzbekistan). The mean age was 6.3 in China (Placebo) and 9.3 in Uzbekistan (control) years, 54% and 52% of them were boys respectively. All children had received broad spectrum antibiotics (cephalosporin) or Macrolides (Azithromycin) and Oxygen. In addition to these we added Prednisolone 1 mg/kg on day 2 of admission to control group. 24 (68.5% from all febrile) children were became afebrile within 24 hours after Predisolone use on day 3 of admission, and their clinical status developed in control group, when it was achieved on day 7 in Placebo group. Hospital days also shortened in control group (6 days) than placebo (8 days) (p value ≤ 0.01). In conclusion, steroid therapy helpful for reducing hospital stay and morbidity in children with community-acquired Pneumonia and no observed side effects.

Keywords: Prednisolone; pediatric pneumonia; hospital day; placebo; corticosteroid; hospitalization; temperature; cough; morbidity.
1. INTRODUCTION

Community-acquired pneumonia afflicts all age groups and although not always bacterial in origin, is clinically versatile, depending on its cause. Pediatric pneumonia is also common, and first-line treatment is still amoxicillin, followed closely by cephalosporin or Macrolides. The definition of CAP varies between different sources; on a pathological level, pneumonia is considered infection of the lung parenchyma, i.e., lower respiratory tract (LRT) infection by microorganisms [2]. CAP is defined clinically as “the presence of signs and symptoms of pneumonia in a previously healthy child due to an infection which has been acquired outside hospital” by both the British Thoracic Society (BTS) [3]. CAP is an alveolar infection that develops in the outpatient setting or within 48h of admission to a hospital. Worldwide, pneumonia was responsible for 15% of childhood deaths in 2013, with highest incidence in developing countries [4]. The global annual incidence of pneumonia is 150 to 156 million cases, accounting for approximately 10-20 million hospitalizations. Physical signs of pneumonia are predominantly tachypnea, fever and crackles, rhonchi, or bronchial breath sounds, which can be heard on auscultation [5]. The gold standard usually considered in the investigation of predictive signs of pneumonia is radiologically-confirmed pneumonia. Radiologic findings consistent with pneumonia include pulmonary infiltrate, either alveolar or interstitial [6]. Prolonged hospitalization could be associated with unfavorable outcomes and is also a cost burden to the public. Several preventable risk factors have been reported to be associated with prolonged hospitalization among children with severe community acquired pneumonia. Failing to exclusively breastfeed for the first 6 months, inappropriate complimentary feeding, anemia, malnutrition, exposure to parental smoking, inadequate antibiotic use, lack of awareness of parents, overuse of nonsteroidal anti-inflammatory drugs, and indoor air pollution contribute to prolonging duration of hospitalization. In my opinion, the accelerated recovery of wellbeing and reduction of hospital stay is of major added value. In European countries, the median estimated cost of median length of stay ranges from €1200 to €6900, with most of the expenses being related to hospital stay and staff [7]. Therefore, the corticosteroid-associated reduction in length of hospital stay should translate into substantial cost savings. Likewise, reduction in the use of antibiotics is potentially of major added value for the community.

2. METHODS

Placebo-controlled, parallel group clinical trials.

Inclusion criteria: All patients with symptoms and signs indicative of pneumonia at admission, including fever (>38.4°C per axilla), cough, and abnormal breath sounds on auscultation.

Exclusion criteria are permanent inability for informed consent, active intravenous drug use, acute burn injury, gastrointestinal bleeding within the past 3 months, known adrenal insufficiency, severe immunosuppression defined as one of the following: infection with human immunodeficiency virus and a CD4 cell count below 350 cells per μL, immunosuppressive therapy after solid organ transplantation, cystic fibrosis, or active tuberculosis.

We collected dependent variables like demographics (age, sex, and address) of the child; clinical presentation (cough, fever, difficulty breathing, grunting, cyanosis, convulsions, inability to feed, and change in level of consciousness), previous history of similar problem, immunodeficiency (HIV, malnutrition, and diabetes mellitus), physical examination (vital signs, nutritional status, intercostal or subcostal retraction, nasal flaring, chest in-drawing, wheezing, crepitations, bronchial breath sounds, cyanosis, signs of rickets, and mental status), and laboratory results (white blood cell count, absolute neutrophil count, hemoglobin, platelet count, C-reactive protein, erythrocyte sedimentation rate, and blood culture). The children are followed during their stay in the hospital for evaluation of oxygen requirement, antibiotics therapy, feeding, and persistency of fever, tachypnea, and duration of hospital stay and treatment outcome.

Eligible patients will be assigned (1:1 ratio) to receive either 1mg/kg of Prednisolone or placebo daily for 3-4 days. All children in an infectious diseases hospital of Andijan had received Prednisolone 1 mg/kg i/v, they are control group. Children admitted to the 2nd hospital of Shandong University considered as a placebo group. Statistical analyses were performed using SPSS software (version 23.0). Normal distribution data were expressed as mean ± SD (x±s). Independent-Samples T-test was used to compare these data. Statistical significance was defined as P<0.05.
3. RESULTS

We had 46 children in China, 2nd hospital of Shandong University who were not admitted Prednisolone – placebo group, and 43 children in an infectious diseases of Andijan region admitted Prednisolone (1mg/kg intravenously) – control group. Placebo group patients’ mean age was 6.3, (5 to 15 years old), 25 of them were boys. Fig. 1. All children had been radiologically confirmed with pneumonia. 21.7% of them were admitted CPAP (increased RR), and no complications. 8 of them were observed recurrences within 1 month with Pneumonia. Average hospital stay was 8 days, maximal is 22 days. 5 children had only increased temperature, 9 patients with cough, and 32 with both symptoms (cough + temperature). Fig. 2, 13 patients had increased WBC.

The control group patients are 43, 22 of them were boys, the mean age was 9.3. Fig. 3.

All had radiologic confirmed Pneumonia, with increased RR. 8 children took CPAP, no recurrences. From the 2nd day of admission they took Prednisolone 1mg/kg intravenously, during the 4-5 days. 14 children had increased temperature on admission day, 9 with cough, 17 had both symptoms. Fig. 4.

**Outcomes:** 52.5% children with increased temperature (from 40) was afebrile on 4th day of admission, in placebo group. In contrast, 68.5% of patients from the control group achieved that on day 3. Fig. 5.

Placebo group children (56.8%) had been taken their cough at 7th day, when it was observed almost in all children (92.5%) in Control group Fig. 6.

4. DISCUSSION

The favourable benefit-to-risk ratio noted with corticosteroids in this trial is in line with findings from trials done in Egypt [8], Italy [9], Japan [10], the Netherlands [11] and Spain [12] etc. Only one trial did not show benefit from corticosteroids [13]. Data from these trials accounting for 1379 adults with community-acquired pneumonia showed that adjunct treatment with corticosteroids reduced length of hospital stay (mean difference –1·10 days, 95% CI –1·86 to –0·34;) [14].

---

**Fig. 1. Placebo group patients**

**Table 1. The mean difference of patients**

| Variables          | Placebo group | Control group | Mean Difference |
|--------------------|---------------|---------------|----------------|
| Hospital days      | 8             | 5.93          | 2.07***        |
| Temperature days   | 4.43          | 1.86          | 2.57***        |
| Cough days         | 6.52          | 3.0           | 3.52***        |
| Number of observations | 46         | 44            |                |

*Note: Mean differences for selected variables between two group patients were estimated using independent samples T-test. *** and ** denote significance at 0.01, 0.05, and 0.10 levels, respectively*
Fig. 2. Placebo group patients' symptoms on admission

Fig. 3. Control group patients

Fig. 4. The control group patients' symptoms on admission
Among children with bacterial pneumonia, corticosteroids reduced early clinical failure rates (defined as for adults, RR 0.41, 95% CI 0.24 to 0.70; high-quality evidence) based on two small, clinically heterogeneous trials, and reduced time to clinical cure [15]. People with CAP treated with corticosteroids had lower clinical failure rates (death, worsening of imaging studies, or no clinical improvement), shorter time to cure, a shorter hospital stay, and fewer complications [15]. Claudine Angela Blum and colleagues report that 7-day treatment with 50 mg oral prednisone daily hastened recovery and hospital discharge in adults with community-acquired pneumonia of any severity [16].

A 2011 Cochrane review that included relevant CAP studies through the year 2010 showed that corticosteroid use accelerates time to symptom resolution and clinical stability, with infrequent adverse effects [17]. Similarly, a 2015 systematic review by Siemie-Niuk and colleagues included...
studies from 2011 through mid-2015 [18]. Their analysis of 13 randomized controlled trials found significantly decreased mortality in severe pneumonia, decreased need for mechanical ventilation, decreased occurrence of acute respiratory distress syndrome, decreased time to clinical stability, and shorter duration of hospitalization [6].

A Spanish study was performed as a multicenter, randomized, double-blinded, parallel-group, placebo-controlled clinical trial. Sixty children, aged from 1 month to 14 years, with CAP and pleural effusion were included. Those authors described faster recovery rate, measured objectively in hours, in the group that received dexamethasone (DXM) 0.15 mg/kg, every 6 h, for 48 h, plus cefotaxime, when compared with the control group. There were no significant differences in adverse events attributable to the study drugs, except for hyperglycemia. Therefore, the authors concluded that DXM appeared to be a safe and effective adjunctive therapy for decreasing the time to recovery in children with parapneumonic pleural effusion [19]. Another study included children with severe CAP: 29 patients received a 5-day methylprednisolone course plus imipenem and 30 patients received imipenem plus placebo. The authors reported that the methylprednisolone group had a faster resolution of symptoms [20]. A recent systematic review identified four randomized controlled trials that included 310 children; corticosteroids reduced early clinical failure rates (RR 0.41 [95% CI: 0.24---0.70]; high-quality evidence based on two small, clinically heterogeneous trials, and reduced time to clinical cure [15]. To date, the role of corticosteroids in adjunctive chemical therapy of childhood CAP is yet to be established. Further support is needed to recommend the use of corticosteroids in clinical practice across distinct severity subgroups and in association with different antibiotics, especially β-lactams [21].

Korean scientists concluded that corticosteroid treatment appeared to be temporally associated with clinical and radiographic improvement, and may be helpful for reducing morbidity in children with macrolide-nonresponsive severe MP. Adjunct corticosteroid therapy was associated with treatment failure among children diagnosed with CAP who did not have underlying asthma [22].

From the rapid improvements of clinical symptoms and pulmonary lesions in the severe MP patients treated with corticosteroids, it has been proposed that cell-mediated immunity plays an important role in the progress of MP [23]. Studies of immune status in MP infection show a low incidence of MP in immunocompromised patients [24], and pulmonary lesions are usually minimal in immunodeficient children [25]. In animal studies, mycoplasma pulmonary lesions in cell-mediated immunity deficient animals induced by thymectomy, irradiation, or antithymus sera were significantly less severe than those in controls [26]. In other experimental Mycoplasma pneumoniae models, interleukin-2 was postulated to play a crucial role in the development of pulmonary lesions [27]. M. pulmonis-infected mice treated with minocycline and prednisolone had lower pulmonary lesion scores than mice treated with minocycline alone [28]. Abnormalities of cell-mediated immunity, including transient anergy to purified protein derivative (PPD), are described in adults as well as children after MP [29]. Pathological studies also provide evidence of cell-mediated immunity for MP pneumonia. When experimental animals are infected with mycoplasma, a large number of lymphocytes, mainly CD4 T-cells, initially infiltrate the peribronchiolar and perivascular regions, with phagocytes appearing later in the bronchiolar lumens [30,31].

These observations suggest that cell-mediated immunity plays an important role in the development of progressive pulmonary lesions in severe MP. Corticosteroid therapy may render great benefit in helping to reduce morbidity in children with severe macrolide-non-responsive MP [32].

Rapid resolution of infection in 86 out of 90 children with complicated MPP who received systemic steroids [33]. Prednisolone appears to be the most effective corticosteroid in the adjunctive therapy of CAP, as it inhibits platelet activation in vitro by a non-genomic mechanism not shared with other types of corticosteroids [34]. Use of steroids could lead to earlier clinical and radiological resolution than antibiotics alone [35]. A recent large multicenter retrospective study in Japan identified 2,228 adult patients with MPP. The effects of low-dose and high-dose corticosteroid therapies on mortality, hospital length of stay (LOS), drug costs and hyperglycemia requiring insulin treatment of MPP were evaluated. However, adjunctive corticosteroid therapy did not decrease 30-day mortality. In addition, both low-dose and high-dose corticosteroid therapies were associated
with increases in LOS. Furthermore, hyperglycemia requiring insulin treatment and drug costs increased with corticosteroid use [36]. Therefore, currently, the benefits of treating MPP patients with steroids needs further study. It has shown positive effects in children [37].

5. CONCLUSION

Our small research has showed that corticosteroid therapy in children helped to reduce morbidity and hospital stay. Unanswered issues remain, on which researchers should focus their attention. First, evidence for a benefit from corticosteroids in outpatients with community-acquired pneumonia is still missing; second, the survival benefit of corticosteroids in patients with community-acquired pneumonia in the ICU still needs large confirmatory trials. Finally, researchers should also investigate any possible long-term benefit from corticosteroids owing to the growing evidence of long-term sequelae following severe infections.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the author and producers of the products because we don’t intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not founded by the producing company rather it was founded by personal efforts of the authors.

CONSENT AND ETHICAL APPROVAL

As per international standard or university standard guideline patients consent and ethical approval has been collected and preserved by the authors.

ACKNOWLEDGEMENTS

Foremost, I would like to acknowledge and express my sincere gratitude to my advisor Professor Zhang Zhao Hua. Her commitment to improving the lives of children and her personal integrity, generosity, patience, and good humor, have all set standards that I sincerely hope to emulate. I would like to highlight and gratitude to my friends Sarvar Pulatov, Ulugbek Turgunov, Qodiri Qobiljonov from Infectious diseases of Andijan region, Dr. Imran from Shandong University, who helped and guided me to perform this job. Without their support, this study was simply not possible.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Grief SN, Loza JK. Prim Care - Clin Off Pract. 2018;45:485–503.
2. Lodha R, Kabra SK, Pandey RM. Cochrane Database Syst Rev; 2013.
3. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. Thorax 66; 2011.
4. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Lancet. 2015;385:430–440.
5. Brar NK, Niederman MS, Ther Adv Respir Dis. 2011;5:61–78.
6. Nascimento-Carvalho CM, J Pediatr (Rio J). 2020;96:29–38.
7. Ostermann H, Garau J, Medina J, Pascual E, McBride K, Blasi F. BMC Pulm Med. 2014;14.
8. Sabry NA, Omar EED, Pharmacol amp; Pharm. 2011;02:73–81.
9. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Am J Respir Crit Care Med. 2005;171:242–248.
10. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, et al. Sakamoto, Lung. 2007;185:249–255.
11. Meijvis SCA, Hardeman H, Remmelts HHF, Heijligenberg R, Rijkers GT, Van Velzen-Blad H, et al. Lancet. 2011;377:2023–2030.
12. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. JAMA - J Am Med Assoc. 2015;313:677–686.
13. Snijders D, Daniels JMA, De Graaff CS, Van Der Werf TS, Boersma WG. Am J Respir Crit Care Med. 2010;181:975–982.
14. Annane D. Lancet. 2015;385:1484–1485.
15. Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M, Cochrane Database Syst Rev; 2017.
16. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Lancet. 2015;385:1511–1518.
17. Yuanjing C, Pu H, Wu T, Cochrane Database Syst Rev; 2009.
18. Siemieniuk RAC, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Intern Med. 2015;163:519–528.
19. Tagarro A, Otheo E, Baquero-Artigao F, Navarro ML, Velasco R, Ruiz M, et al. J Pediatr. 2017;185:117-123.e6.
20. Nagy B, Gaspar I, Papp A, Bene Z, Vokó Z, Balázs G. Pediatr Pulmonol. 2013;48: 168–175.
21. Nascimento-Carvalho AC, Nascimento-Carvalho CM, Expert Opin. Pharmacother. 2019;20:435–442.
22. Ambroggio L, Test M, Metlay JP, Graf TR, Blosky MA, Macaluso M, et al. J Pediatric Infect Dis Soc. 2015;4:21–27.
23. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. Infect Clin Dis an Off Publ Infect Dis Soc Am. 2000;31:1507–1511.
24. Tarp B, Jensen JS, Østergaard L, Andersen PL. Respir Eur J. 1999;13: 175–179.
25. Foy HM, Ochs H, Davis SD, Kenny GE, Ralph R, The S, et al. 2017;127:388–393.
26. Denny FW, Taylor-Robinson D, Allison AC, Med J. Microbiol. 1972;5:327–336.
27. Tanaka H, Honma SI, Abe S, Tamura H. Am J Respir Crit Care Med. 1996;154: 1908–1912.
28. Tanaka H, Okada H, Yamagishi M, Honma S, Sugawara H, Abe S, et al. Nihon Kyobu Shikkan Gakkai Zasshi. 1994;32:42–47.
29. Tanaka H, Koba H, Honma S, Sugaya F, Abe S. Eur Respir J. 1996;9:669–672.
30. Taylor G, Soc JR. Med. 1979;72:520–526.
31. Opitz O, Pietsch K, Ehlers S, Jacobs E. Immunobiology. 1997;196:575–587.
32. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, In Pediatr Pulmonol. 2006;263–268.
33. Youn YS, Lee SC, Rhim JW, Shin MS, Kang JH, Lee KY. Infect Chemother. 2014;46:239–247.
34. Liverani E, Banerjee S, Roberts W, Naseem KM, Perretti M. Biochem Pharmacol. 2012;83:1364–1373.
35. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Allergy Asthma Immunol Res. 2014;6: 22–26.
36. Tashiro M, Fushimi K, Kawano K, Takazono T, Saijo T, Yamamoto K, et al. BMC Pulm Med. 2017;17:1–10.
37. Bajantri B, Venkatram S, Diaz-Fuentes G. J Clin Med Res. 2018;10:535–544.